Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy

The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.

Syndax announced results of the Phase I/II AUGMENT-101 trial of revumenib in acute leukemias • Source: Shutterstock

More from Clinical Trials

More from R&D